Alopecia areata—New updates with long‐term use of JAK inhibitors

2021 ◽  
Author(s):  
Cristina Nguyen ◽  
Natasha Atanaskova Mesinkovska
Keyword(s):  
Alopecia Areata ◽  
Jak Inhibitors

Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study

2015 ◽  
Vol 28 (5) ◽  
pp. 309-317 ◽  
Author(s):  
Jovan Lalosevic ◽  
Mirjana Gajic-Veljic ◽  
Branka Bonaci-Nikolic ◽  
Milos Nikolic
Keyword(s):  
Topical Corticosteroid ◽  
Corticosteroid Therapy ◽  
Alopecia Areata ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals JAK Inhibitors for the Treatment of Pediatric Alopecia Areata

2020 ◽  
Vol 20 (1) ◽  
pp. S31-S36
Author(s):  
Claire E. Hamilton ◽  
Brittany G. Craiglow
Keyword(s):  
Alopecia Areata ◽  
Jak Inhibitors

Alopecia areata: A long term follow-up study of 191 patients

2006 ◽  
Vol 55 (3) ◽  
pp. 438-441 ◽  
Author(s):  
Antonella Tosti ◽  
Sara Bellavista ◽  
Matilde Iorizzo
Keyword(s):  
Alopecia Areata ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals Methotrexate in Severe Childhood Alopecia Areata: Long-term Follow-up

2016 ◽  
Vol 96 (1) ◽  
pp. 102-103 ◽  
Author(s):  
P Lucas ◽  
C Bodemer ◽  
S Barbarot ◽  
P Vabres ◽  
M Royer ◽  
...  
Keyword(s):  
Alopecia Areata ◽  
Long Term Follow Up

A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

2017 ◽  
Vol 21 (6) ◽  
pp. 562-563 ◽  
Author(s):  
Maya Deeb ◽  
Renée A. Beach
Keyword(s):  
Alopecia Areata ◽  
Janus Kinase ◽  
Local Administration ◽  
Jak Inhibitors ◽  
Management Options ◽  
Current Management ◽  
Extensive Disease ◽  
Extrinsic Factors ◽  
Intrinsic Factors ◽  
Attractive Option

Alopecia areata (AA) is an autoimmune-mediated, nonscarring form of hair loss. Despite its prevalence, current management options are limited, especially when the disease has progressed to alopecia totalis (AT) or alopecia universalis (AU). Recent evidence that janus kinase (JAK) signaling contributes to AA pathogenesis prompted the investigation of JAK inhibitors such as tofacitinib and ruxolitinib as possible oral treatments. However, the potential for significant adverse effects with systemic JAK inhibition makes local administration a more attractive option. Yet, a paucity of data exists on topical JAK inhibition in AA. A success of topical ruxolitinib (0.6% cream) use in a young patient with AU has been reported to date. Here we report the treatment of a 66-year-old with AA with the same formulation of topical ruxolitinib, where it failed to induce hair growth. Our report demonstrates the importance of examining the factors contributing to variation in treatment response in a clinical trial of topical JAK inhibitors in AA. It is likely that both intrinsic factors specific to individual patients and extrinsic factors relating to treatment regimen are involved. Furthermore, characterisation of the specific JAKs overexpressed in AA may better target medication. Finally, this report highlights the need to compare the outcomes of topical vs oral ruxolitinib administration in patients with severe AA, AT, and AU and may support the possibility that extensive disease is more adequately treated with oral administration of ruxolitinib.

Sign in / Sign up

Export Citation Format

Share Document